Human Genome Sciences, Inc and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal phase 3 trials of Benlysta (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).
The data, which will be presented today in Philadelphia at the 73rd Annual Scientific Meeting of the American College of Rheumatology (ACR), demonstrate that, in BLISS-52, belimumab plus standard of care achieved a clinically and statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Study results also show that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
“The BLISS-52 phase 3 results presented at ACR demonstrate that the efficacy of treatment with Benlysta plus standard of care was superior to that of placebo plus standard of care,” said David C Stump, Executive Vice President, Research and Development, HGS.
“These data were statistically significant and were strongly supported across multiple measures of clinical effect and multiple time-points. Of note, a greater percentage of patients receiving Benlysta were able to reduce their use of steroids.”
Carlo Russo, Senior Vice President, Biopharm Development, GSK, said: “We have been pleased by the consistency of benefit demonstrated by belimumab in the BLISS-52 study, and we hope to confirm these results in the second phase 3 study which is to report shortly. We very much hope that we will be able to deliver a new option for the treatment of this debilitating disease.”
To find out more, please click on the link below: